Skip to main content

FUCA2 Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-41286

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP3-41286

Key Product Details

Species Reactivity

Human

Applications

Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit

Concentration

0.5 mg/ml

Product Specifications

Immunogen

Immunized with recombinant Human FUCA2 (Uniprot#: Q9BTY2; Glu81-Ile467 (Uniprot#: Q9BTY2)

Clonality

Polyclonal

Host

Rabbit

Applications for FUCA2 Antibody

Application
Recommended Usage

Immunocytochemistry/ Immunofluorescence

5-20ug/mL

Immunohistochemistry

5-20ug/mL

Western Blot

0.2-2ug/mL

Formulation, Preparation, and Storage

Purification

Antigen and protein A Affinity-purified

Formulation

0.01M PBS, pH7.4, 50% glycerol

Preservative

0.05% Proclin 300

Concentration

0.5 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: FUCA2

Alpha-L-fucosidase is responsible for hydrolyzing the alpha-1,6-linked fucose joined to the reducing-endN-acetylglucosamine of the carbohydrate moieties of glycoproteins

Long Name

alpha-L-Fucosidase 2

Alternate Names

A-L-Fucosidase 2, Alpha-L-fucosidase 2, Alpha-L-fucoside fucohydrolase 2, dJ20N2.5, EC 3.2.1.51, fucosidase, alpha-L- 2, plasma, MGC1314, plasma alpha-L-fucosidase, Plasma Fucosidase

Gene Symbol

FUCA2

Additional FUCA2 Products

Product Documents for FUCA2 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for FUCA2 Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...